Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McGill University
$105,000.00
Molecular Genetic Analyses of Chromosome 3p Genes in Epithelial Ovarian Cancer
EF 2008-09
Résumé
Deletions involving chromosome 3p occur in all forms of epithelial ovarian cancer (EOC), including benign, low malignant potential (LMP), and highly malignant tumours, indicating that tumour suppressor genes (TSGs) important in EOC likely reside in this location. Indeed, it has been shown that the introduction of 3p fragments can suppress tumourigenicity of an EOC cell line lacking a copy of the 3p arm.
In order to elucidate the role of chromosome 3p genes in EOC, gene expression profiles of normal ovarian surface epithelial cells were compared to expression profiles of both high-grade malignant tumours and LMP tumours. Several genes were identified in both analyses and were also observed to be upregulated in a functional model of EOC when tumourigenicity was suppressed. Of these, WNT5A is an intriguing candidate as it controls an important signaling pathway and displays tumour suppressor ability in several types of cancer.
To examine the ability of WNT5A to suppress tumourigenicity in EOC, I will use three EOC cell lines with different genetic backgrounds representing the different histopathological subtypes of EOC. The cells will be treated with purified protein and effects on morphology and tumourigenicity will be measured. If results imply that suppression of tumourigenicity has occurred, expression microarray analyses will be performed to investigate downstream effects of the WNT5A signaling pathway. In addition, protein expression will be assayed to relate expression to clinical variables, such as the grade of the tumour, stage and subtype of the disease, and response to chemotherapy.
EOC has a poor prognosis, as many tumours are diagnosed at a late stage where the 5-year survival rate is < 20%. Early events leading to tumourigenicity are not well understood. A deeper understanding of the genetic events leading to tumourigenicity and malignancy may identify new disease markers and drug targets, resulting in earlier diagnosis and more effective treatments.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
184348
Name
Birch Ashley H
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Molecular Genetic Analyses of Chromosome 3p Genes in Epithelial Ovarian Cancer
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Affymetrix Microarray; Chromosome 3; Genotyping Snp Array; Loss Of Heterozygosity; Low Malignant Potential; Malignant Ovarian Cancer; Response To Therapy; Tumour Suppressor Genes; Tumourigenicity Assays; Wnt5a
Abstract
Deletions involving chromosome 3p occur in all forms of epithelial ovarian cancer (EOC), including benign, low malignant potential (LMP), and highly malignant tumours, indicating that tumour suppressor genes (TSGs) important in EOC likely reside in this location. Indeed, it has been shown that the introduction of 3p fragments can suppress tumourigenicity of an EOC cell line lacking a copy of the 3p arm.
In order to elucidate the role of chromosome 3p genes in EOC, gene expression profiles of normal ovarian surface epithelial cells were compared to expression profiles of both high-grade malignant tumours and LMP tumours. Several genes were identified in both analyses and were also observed to be upregulated in a functional model of EOC when tumourigenicity was suppressed. Of these, WNT5A is an intriguing candidate as it controls an important signaling pathway and displays tumour suppressor ability in several types of cancer.
To examine the ability of WNT5A to suppress tumourigenicity in EOC, I will use three EOC cell lines with different genetic backgrounds representing the different histopathological subtypes of EOC. The cells will be treated with purified protein and effects on morphology and tumourigenicity will be measured. If results imply that suppression of tumourigenicity has occurred, expression microarray analyses will be performed to investigate downstream effects of the WNT5A signaling pathway. In addition, protein expression will be assayed to relate expression to clinical variables, such as the grade of the tumour, stage and subtype of the disease, and response to chemotherapy.
EOC has a poor prognosis, as many tumours are diagnosed at a late stage where the 5-year survival rate is < 20%. Early events leading to tumourigenicity are not well understood. A deeper understanding of the genetic events leading to tumourigenicity and malignancy may identify new disease markers and drug targets, resulting in earlier diagnosis and more effective treatments.
Competitiondate
200810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Birch, Ashley H
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~